#LyX 2.1 created this file. For more info see http://www.lyx.org/
\lyxformat 474
\begin_document
\begin_header
\textclass article
\use_default_options true
\maintain_unincluded_children false
\language english
\language_package default
\inputencoding auto
\fontencoding global
\font_roman default
\font_sans default
\font_typewriter default
\font_math auto
\font_default_family default
\use_non_tex_fonts false
\font_sc false
\font_osf false
\font_sf_scale 100
\font_tt_scale 100
\graphics default
\default_output_format default
\output_sync 0
\bibtex_command default
\index_command default
\paperfontsize default
\use_hyperref false
\papersize default
\use_geometry false
\use_package amsmath 1
\use_package amssymb 1
\use_package cancel 1
\use_package esint 1
\use_package mathdots 1
\use_package mathtools 1
\use_package mhchem 1
\use_package stackrel 1
\use_package stmaryrd 1
\use_package undertilde 1
\cite_engine basic
\cite_engine_type default
\biblio_style plain
\use_bibtopic false
\use_indices false
\paperorientation portrait
\suppress_date false
\justification true
\use_refstyle 1
\index Index
\shortcut idx
\color #008000
\end_index
\secnumdepth 3
\tocdepth 3
\paragraph_separation indent
\paragraph_indentation default
\quotes_language english
\papercolumns 1
\papersides 1
\paperpagestyle default
\tracking_changes false
\output_changes false
\html_math_output 0
\html_css_as_file 0
\html_be_strict false
\end_header

\begin_body

\begin_layout Title
Gene expression methods for cancer cell line drug sensitivity and patient
 outcome
\end_layout

\begin_layout Standard
\begin_inset Note Note
status open

\begin_layout Plain Layout
main work for this chapter are investigating the COREAD data set with available
 methods
\end_layout

\begin_layout Plain Layout
(not sure to remove patient survival)
\end_layout

\begin_layout Plain Layout
- intro: while intro chapter had overview of all methods used, these are
 the methods we use here
\end_layout

\begin_layout Plain Layout
- include all methods here that are common to the next chapters
\end_layout

\begin_layout Plain Layout
- describe how I actually obtained scores per method and how I ran it
\end_layout

\begin_layout Plain Layout
- reproduce already published results that are easy (e.g.
 have got all the utils for gdsc mutation assocs)
\end_layout

\begin_layout Plain Layout
.
\end_layout

\begin_layout Plain Layout
atn: 
\begin_inset Quotes eld
\end_inset

Unbiased approach is not interpretable
\begin_inset Quotes erd
\end_inset


\end_layout

\begin_layout Plain Layout
w/ subchapters:
\end_layout

\begin_layout Plain Layout
- gdsc drug response
\end_layout

\begin_layout Plain Layout
- tcga survival
\end_layout

\begin_layout Plain Layout
- drug sensitisation
\end_layout

\begin_layout Plain Layout
.
\end_layout

\begin_layout Plain Layout
1 intro per chapter +
\end_layout

\begin_layout Plain Layout
1 aims per section?
\end_layout

\end_inset


\end_layout

\begin_layout Part
A Baseline for available Pathway Methods
\end_layout

\begin_layout Section
Aim
\end_layout

\begin_layout Standard
Pathway methods have been used for a while in a cancer context, both for
 cell lines an primary tumours.
 Most of the time, the method of choice is to take a gene set from either
 Gene Ontology (GO) 
\begin_inset CommandInset citation
LatexCommand cite
key "Ashburner2000-xl"

\end_inset

, KEGG 
\begin_inset CommandInset citation
LatexCommand cite
key "Kanehisa2000-mp"

\end_inset

 or Reactome 
\begin_inset CommandInset citation
LatexCommand cite
key "Croft2011-po"

\end_inset

, and calculate a combined expression score using either a Fisher's exact
 test (e.g.
 by a tool called DAVID **cite**) if one is to test one set against another,
 or some variant of Gene Set Enrichment Analysis (GSEA) 
\begin_inset CommandInset citation
LatexCommand cite
key "Subramanian2005-wp"

\end_inset

 if the sets are pre-defined, but one wants to avoid cutting of continuous
 expression values at an artbitrary threshold.
 There are, however, more advanced pathway methods available that take into
 account the directionality and sign of edges in a KEGG pathway (Signaling
 Pathway Impact Analysis 
\begin_inset CommandInset citation
LatexCommand cite
key "Tarca2008-ey"

\end_inset

, Differential Expression Analysis for Pathways 
\begin_inset CommandInset citation
LatexCommand cite
key "Haynes2013-eo"

\end_inset

), calculate probable information flow between the set items (Pathifier,
 
\begin_inset CommandInset citation
LatexCommand cite
key "Drier2013-vn"

\end_inset

), or employ a bayesian framework that models translation, activity, and
 interactions (PARADIGM, 
\begin_inset CommandInset citation
LatexCommand cite
key "Vaske2010-zn"

\end_inset

).
 I will leave the more complex methods for a later chapter and focus on
 GSEA using different gene sets here.
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
add gsea schema here...
 (maybe still switch to GSVA?)
\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
GSEA
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
GSEA using GO gene sets is ubiquitous: usually, a (for instance) differential
 expression analysis yields a list of genes, yet it is not clear which higher-le
vel function they mediate.
 One run of GSEA/GO later, our list of genes is condensed down to a list
 of significantly enriched GO categories, that may be related to the phenotype
 we are observing.
 This may work very well in some cases.
 There are, however, a couple of caveats to observe: (1) a gene does not
 exclusively belong to one process; we might very well get a significant
 p-value only caused by the overlap between different sets, (2) if we test
 all categories and correct by false discovery rate we might dilute our
 signal so much that small categories can no longer be significant, or (3)
 they process that did indeed cause our phenotype does not correspond to
 a gene set at all (this can be due to missing biological knowledge, annotation
 errors, or simply the fact that curators have not yet added a certain gene
 to a certain category).
 Maybe the most dangerous caveat of them all is that once we see our list
 of resulting categories, we are inclined to pick out category that 
\begin_inset Quotes eld
\end_inset

makes sense
\begin_inset Quotes erd
\end_inset

.
 Taken this selection of desired categories on its head, we may also be
 inclined to overlook a category that we don't want to see, e.g.
 because the involved process is already known in literature and we could
 not publish our new findings in a high-impact journal.
\end_layout

\begin_layout Standard
I will use this chapter to provide a baseline of using Gene Set Enrichment
 Analysis in order to figure out which processes are involved in: (1) making
 cancer cell lines sensitive or resistant to different drugs in the GDSC
 panel 
\begin_inset CommandInset citation
LatexCommand cite
key "Garnett2012-dk,Iorio2016-gh"

\end_inset

, (2) causing improved or diminished survival in cancer patients in the
 TCGA cohorts 
\begin_inset CommandInset citation
LatexCommand cite
key "The_Cancer_Genome_Atlas_Research_Network2013-bi"

\end_inset

, and (3) which two drugs are likely to act synergistically when treating
 cancer cell lines.
 I will not filter the gene sets I use, and well represented signaling pathways
 are among the top hits for (1) - where signaling pathways are known to
 play a pivotal role for targeted therapies 
\begin_inset CommandInset citation
LatexCommand cite
key "Garnett2012-dk,Iorio2016-gh,Yap2012-mi"

\end_inset

 and (2) - where signaling pathways are at the core of disease development
 and progression 
\begin_inset CommandInset citation
LatexCommand cite
key "Hanahan2000-is,Hanahan2011-he,Hanahan2012-im"

\end_inset

.
 For (3), I will see how well cancer drugs are represented in the hits obtained,
 as the combinatorial targeting of multiple cancer-related signaling pathways
 has been shown to ***.
\end_layout

\begin_layout Section
Pathways and Cell Line Drug Response
\end_layout

\begin_layout Subsection
Methods
\end_layout

\begin_layout Subsubsection
Obtaining Gene Sets
\end_layout

\begin_layout Standard
To obtian Gene Ontology sets, I used the BioMart R package [cite] to query
 the Ensembl [cite] hsapiens_gene_ensembl database for all HGNC symbols
 that had a Gene Ontology 
\begin_inset CommandInset citation
LatexCommand cite
key "Ashburner2000-xl,Gene_Ontology_Consortium2004-sn"

\end_inset

 ID (go_id field) associated with them, yielding three main categories (biologic
al process, molecular function, cellular compartment) with XX, XX, and XX
 gene sets respecively.
 I performed the subsequent analyses using gene sets from the biological
 process category only.
 For Reactome 
\begin_inset CommandInset citation
LatexCommand cite
key "Croft2011-po"

\end_inset

, I downloaded the file ReactomePathways.gmt
\begin_inset Foot
status open

\begin_layout Plain Layout
http://www.reactome.org/pages/download-data/
\end_layout

\end_inset

.
 There were a total of XX pathways covering YY genes.
 
\end_layout

\begin_layout Standard
For other gene sets, I used the Enrichr platform [cite] and the gene sets
 the authors assembled in their Github repository
\begin_inset Foot
status open

\begin_layout Plain Layout
https://github.com/yokuyuki/Enrichr
\end_layout

\end_inset

.
 They encompassed gene sets for 35 pathway and pathway-related sources,
 including Gene Ontology, Reactome (where I queried the original databases
 to obtain more up-to-date gene lists), as well as KEGG 
\begin_inset CommandInset citation
LatexCommand cite
key "Kanehisa2000-mp"

\end_inset

 (that does not suffer from such a drawback as the last public release was
 in 2001, before it went commercial).
 This data source of KEGG gene sets had the advantage that it was in .gmt
 format that was readily accessible and easily machine readable (unlike
 the KGML present in the last official public KEGG release).
\end_layout

\begin_layout Subsubsection
Using Gene Set Enrichment Analysis (GSEA) to obtain scores
\end_layout

\begin_layout Standard
I used the function wGSEA 
\begin_inset CommandInset citation
LatexCommand cite
key "Subramanian2005-pd"

\end_inset

 from the original BROAD weighted GSEA R script (http://software.broadinstitute.or
g/gsea/index.jsp) modified by Fracesco Iorio to work with the current version
 of R.
 I supplied as gene sets the Gene Ontology and pathway sets described above.
 I performed 1,000 resampling steps for score normalisation for all subsequent
 analyses unless otherwise indicated.
 I used the normalised enrichment score (NES) for all subsequent associations,
 which was a continuous numerical value that represented the expression
 level of the gene set in a given sample.
 I did not perform any statistical test to quantify the enrichment of this
 set compared to other sets, as at this point I was only interested in the
 expression level itself, not how it compares to other samples.
\end_layout

\begin_layout Standard
I transformed the resulting distribution of NES scores into a normal distributio
n using a kernel density estimator (R package sROC 
\begin_inset Foot
status open

\begin_layout Plain Layout
https://cran.r-project.org/web/packages/sROC/index.html
\end_layout

\end_inset

) to obtain uniformly distributed scores and a normal transformation afterwards.
 I used those transformed scores in subsequent linear (ANOVA-like) associations
 for drug response.
\end_layout

\begin_layout Subsubsection
Drug Associations using the Half-Maximum Inhibitory Concentration (IC50)
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_ic50.gif
	lyxscale 50
	width 50col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
IC50 values
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
The original GDSC data set contained different dilutions of drugs that the
 cell lines in the panel were subjected, measuring how much it interfered
 with their growth.
 Since I have got a pathway score for each cell line, I also need a single
 value corresponding to the sensitivity to a given drug.
 On way to do this is to measure the growth inhibition at different concentratio
ns, and then fit a dose-response curve to the data points, interpolating
 (or extrapolating, if necessary) the concentration at which the half-maximal
 inhibition occured.
 This term is referred to the IC50 value, and has already been calculated
 in 
\begin_inset CommandInset citation
LatexCommand cite
key "Iorio2016-gh"

\end_inset

.
\end_layout

\begin_layout Standard
I obtained already processed gene expression matrix from the GDSC cell lines
 and their fitted IC50 values to 265 public drugs from 
\begin_inset CommandInset citation
LatexCommand cite
key "Iorio2016-gh"

\end_inset

.
 I performed an ANOVA using the gene set score as an independent variable
 (
\begin_inset Formula $S_{j}$
\end_inset

, where 
\begin_inset Formula $j$
\end_inset

 is the index of the cell line from 
\begin_inset Formula $1$
\end_inset

 to 
\begin_inset Formula $k$
\end_inset

) and the log10 of the IC50 in micro-molar as the response variable (
\begin_inset Formula $D_{i}$
\end_inset

, where 
\begin_inset Formula $i$
\end_inset

 is the drug index).
 I regressed out the contribution of individual tissues by including it
 as a covariate in the fit.
\end_layout

\begin_layout Standard
\begin_inset Formula 
\[
D_{i}\sim T_{j=1..k}+S_{j=1..k}|_{i=1..m}
\]

\end_inset


\end_layout

\begin_layout Standard
I performed this association between every drug and all gene set scores,
 yielding an effect size (how many units of drug response changed per unit
 of enrichment score) and p-value for each pair.
 I corrected the p-values for each pair using the False Discovery Rate (FDR)
 [cite].
 In addition, I performed these associations using each tissue separately:
\end_layout

\begin_layout Standard
\begin_inset Formula 
\[
D_{i}\sim S_{j=1..l,t\in T}|_{i=1..m,t\forall T}
\]

\end_inset


\end_layout

\begin_layout Standard
In this formula, the scores 
\begin_inset Formula $S$
\end_inset

 have a different index from 
\begin_inset Formula $1$
\end_inset

 to 
\begin_inset Formula $l$
\end_inset

, where 
\begin_inset Formula $t$
\end_inset

 corresponds to all cell lines that are in tissue 
\begin_inset Formula $T$
\end_inset

.
 In this case, I corredted the p-values using the FDR methods for each subset
 of tissues separately.
\end_layout

\begin_layout Subsubsection
Volcano Plots
\end_layout

\begin_layout Subsection
Results
\end_layout

\begin_layout Itemize
basically, better versions of the volcano plots that are already there
\end_layout

\begin_layout Itemize
add table of top hits
\end_layout

\begin_layout Itemize
list them in text, implying the ridiculousness
\end_layout

\begin_layout Itemize
probably see where pathways that should be causing this are (=the ones we
 use in speed2 anyway)
\end_layout

\begin_layout Subsubsection
Associations using Mutations
\end_layout

\begin_layout Itemize
ca.
 re-plot of the paper
\end_layout

\begin_layout Subsubsection
Associations using Gene Ontology
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_go_pan.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology Pan-Cancer associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_go_tissue.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology tissue-specific associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsubsection
Associations using KEGG
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_kegg_pan.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology Pan-Cancer associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_kegg_tissue.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology tissue-specific associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsubsection
Associations using Reactome
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_reactome_pan.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology Pan-Cancer associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/2.1_reactome_tissue.png
	lyxscale 50
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Gene Ontology tissue-specific associations
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsection
Discussion
\end_layout

\begin_layout Standard
The importance of mutations, especially when they are drivers, and the associati
on with the cell lines' response to the different drugs is well established.
 Also with the new data set, there are previously unknown links that may
 ultimately lead to new clinical indications, or prioritise the development
 of certain drugs over others.
\end_layout

\begin_layout Standard
In contrast to this, the biological meaning of the top associations between
 gene set or pathway scores and drug response I obtained is doubtful at
 best.
 What does it mean to have an association of the 
\begin_inset Quotes eld
\end_inset

T cell receptor
\begin_inset Quotes erd
\end_inset

 in Head and Neck Squamous Carcinoma (HNSC)? There are no immune cells involved
 in the culturing of HNSC cell lines.
 [add about a q per plot here]
\end_layout

\begin_layout Standard
We thus have two options: we either need to link seemingly unrelated gene
 sets back to the process that actually caused a difference in drug response,
 or we need to pre-select gene sets that may be relevant for drug response.
 Needless to say, the first approach may in mose cases prove impossible,
 as we can not easily follow the chain of causality between a biological
 process that mediates differential drug response and its downstream readout
 as change of gene expression.
 The second alternative does not solve this, but leads to a much higher
 probability to catch causative gene sets when we already select candidates
 of exactly this by prior knowledge.
\end_layout

\begin_layout Section
Pathways and primary Tumours
\end_layout

\begin_layout Subsection
Methods
\end_layout

\begin_layout Subsubsection
Gene Expression Data from the TCGA
\end_layout

\begin_layout Standard
I used the Firehose tool
\begin_inset Foot
status open

\begin_layout Plain Layout
http://gdac.broadinstitute.org/
\end_layout

\end_inset

 from the BROAD institute to download data labelled level 3 RNA-seq v2 (files
 names including RSEM_genes__data.Level_3, unpacked them, selected all files
 contained in the archive that contained the name rnaseqv2) for all cancer
 types for which it was available.
 I extracted the raw counts from each of the text files for each gene.
 I then performed a voom transformation (R package limma 
\begin_inset CommandInset citation
LatexCommand cite
key "Smyth2005-mw"

\end_inset

) for each TCGA study separately.
 The result of this transformation are expression values that I can use
 linear modeling techniques on, unlike the raw RNA-seq read counts.
 With the resulting expression matrix, I selected only genes that had an
 HGNC symbol associated with them.
 I used the function avereps (R package limma) to average rows that had
 the same gene symbol.
 This resulted in one expression matrix per TCGA tissue, for a total of
 00 tissues including 00000 tumor and 0000 matched normal samples.
\end_layout

\begin_layout Subsubsection
Clinical Data from the TCGA
\end_layout

\begin_layout Standard
Also using the Firehose tool, I downloaded clinical data (file names including
 Merge_Clinical.Level_1, unpack them, select all clin.merged.txt files) for
 all cancer types for which it was available.
 I extracted the fields for study (admin.disease_code), age of the patient
 (age_days), their vital status (where a field days_to_death with a missing
 value indicated that the patient was alive, encoded with 0 if the patient
 is alive and 1 if they are not), days that they survived (either patient.days_to
_death or if that was not available patient.days_to_last_followup), the TCGA
 patient barcode (patient.bcr_patient_barcode), and their sex (patient.gender).
 I converted the days of survival to months by dividing by 30.4.
 I discarded all patients that had a negative survival time.
 I removed duplicates, and in the case there were multiple records of the
 same patient I took the one recorded latest (the row where the field patient.day
s_to_birth had the highest number).
\end_layout

\begin_layout Subsubsection
Cox Proportional Hazard Model for Survival Associations
\end_layout

\begin_layout Subsection
Results
\end_layout

\begin_layout Subsubsection
Associations using Mutations
\end_layout

\begin_layout Subsubsection
Associations using Gene Ontology
\end_layout

\begin_layout Subsubsection
Associations using KEGG
\end_layout

\begin_layout Subsubsection
Associations using Reactome
\end_layout

\begin_layout Subsection
Discussion
\end_layout

\begin_layout Section
Pathway-responsive genes: The SPEED Platform
\begin_inset CommandInset label
LatexCommand label
name "sec:Pathway-responsive-genes:SPEED"

\end_inset


\end_layout

\begin_layout Subsection
Methods
\end_layout

\begin_layout Subsubsection
Generating Gene Lists
\end_layout

\begin_layout Standard

\lang british
The authors of the original SPEED publication used four parameters to generate
 gene lists from their input experiments:
\end_layout

\begin_layout Itemize

\lang british
Z-score cutoff: the top n% of upregulated genes
\end_layout

\begin_layout Itemize

\lang british
Total expression cutoff: the top m% of genes considering their basal expression
 in each experiment
\end_layout

\begin_layout Itemize

\lang british
Experiment overlap: the percentage of experiments for which the other two
 conditions must be met
\end_layout

\begin_layout Itemize

\lang british
Uniqueness: whether only genes should be returned that were unique to the
 stimulation of a specific pathway
\end_layout

\begin_layout Standard

\lang british
With the SQLite database (
\begin_inset CommandInset href
LatexCommand href
name "http://speed.sys-bio.net/SPEED_db.zip"
target "http://speed.sys-bio.net/SPEED_db.zip"

\end_inset

) and Python query tools the authors provided, I extracted gene lists with
 the given cutoff.
 First, I used the default parameters in their implementation, which was
 to include all genes that were top 5% of up-regulated genes by z-score,
 overall top 50% of expressed genes, in at least 20% of the experiments
 per pathway, and disregarding whether the gene was in any other pathway
 or not.
\end_layout

\begin_layout Subsubsection

\lang british
Pathway Scores for all Experiments
\end_layout

\begin_layout Standard
I calculated the raw basal GSEA scores (using the wGSEA function of the
 script provided by the BROAD institute) for all cell lines and basal gene
 expression in the GDSC panel using the default gene list as described in
 the previous section.
 As we do not have a background set, we transformed the resulting bimodal
 distribution for each pathway across all cell lines into a normal distribution
 using a kernel density estimator (kCDF function from the R package sROC
 [cite!]).
 The result of this resembled a uniform distribution, with the exception
 that it took into account local differences with the kernel function.
 I then transformed the resulting distribution into a normal distribution
 using the formula
\end_layout

\begin_layout Standard
\begin_inset Formula 
\[
log(x/(1\text{âˆ’}x))
\]

\end_inset


\end_layout

\begin_layout Standard
which yielded normally distributed GSEA scores without performing any test
 of significance in terms of up- or down-regulated of the individual cell
 lines.
\end_layout

\begin_layout Subsubsection

\lang british
Running the Cross-Validation
\end_layout

\begin_layout Standard

\lang british
With the SQLite database (
\begin_inset CommandInset href
LatexCommand href
name "http://speed.sys-bio.net/SPEED_db.zip"
target "http://speed.sys-bio.net/SPEED_db.zip"

\end_inset

) and Python query tools the authors provided, we extracted gene lists for
 different combinations of those four parameters:
\end_layout

\begin_layout Itemize

\lang british
Z-score: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5,
 8, 9, 10, 11, 12, 15, 20, 25
\end_layout

\begin_layout Itemize

\lang british
Total expression: 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100
\end_layout

\begin_layout Itemize

\lang british
Overlap: 5, 10, 20, 30, 40, 50, 60, 70, 80
\end_layout

\begin_layout Itemize

\lang british
Uniqueness: True or False
\end_layout

\begin_layout Standard
For each combination, I performed a scan of the four adjustable platform
 parameters to optimize the order obtained by GSEA scores between control
 and stimulated experiments.
 For combination of parameters, so for each of the 4950 gene lists, I calculated
 the raw enrichment score for each pathway and cell line, yielding a total
 of 55 million enrichment scores.
 I then went on to, for each pathway, construct a precision-recall curve
 that quantified how well the GSEA scores were able assign lower pathway
 activation scores to the control arrays than the perturbed arrays (where,
 in the case of an inhibition I performed GSEA using negative z-scores).
\end_layout

\begin_layout Standard
The set of control arrays comprised all the un-stimulated arrays in the
 database, and the stimulated set all arrays in the database where a certain
 pathway was perturbed.
 I used as a measure of performance the area under the precision-recall
 curve.
 A perfect ordering (that is, all control arrays and then all stimulated
 arrays) corresponded to a precision-recall AUC (prAUC) of 1, while a random
 ordering would respond to a prAUC about 0.5.
 
\end_layout

\begin_layout Standard
By using not only the matched control arrays to the perturbed arrays but
 all arrays present in the data set, we allow cross-activation of pathways
 while minimizing the fit to random differences in gene expression by different
 initial conditions.
\end_layout

\begin_layout Standard
I split the data set (both control and perturbed arrays) in five different
 subsets, where four of the five were the designated training set and the
 fifth the designed test set.
 I calculated the prAUC for all the parameters described in the previous
 section, and chose the set with the highest score.
 I then went on to the part that was not used in training and quantified
 the prAUC there as well.
 I performed the whole process five times, with another subset functioning
 as the test set each time.
 I then chose the set that the highest prAUC:
\end_layout

\begin_layout Standard
\begin_inset Formula 
\[
selected=max^{all\,runs}(min^{per\,run}(prAUC^{train},prAUC^{test}))
\]

\end_inset


\end_layout

\begin_layout Standard
I did not simply select the highest highest AUC in the test set because
 I would not want to select a model that performed badly on the training
 set to begin with.
\end_layout

\begin_layout Subsubsection

\lang british
Linear Associations
\end_layout

\begin_layout Standard

\lang british
As a control and sanity check, I compared the inferred pathway activation
 scores between different tissues.
 If the assigned scores per tissue are biologically meaningful, we would
 expect to find well-established literature evidence for backing them up.
 A heatmap overview of pathway activation scores is shown in figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "fig:tissue-heatmap"

\end_inset

.
\end_layout

\begin_layout Standard
I calculated a linear regression using the obtained pathway scores the IC50s
 or drug response for all cell lines and each pathway, with tissues either
 as a blocking factor or calculating the associations for each tissue separately.
 I adjusted p-values by controlling the false discovery rate and visualized
 the result as volcano plots and individual fits.
 For separate fits between tissues, I only calculated associations that
 had at least two sensitive cell lines (defined as it being in the top 10%
 of responders, not 100x less sensitive than the most sensitive overall,
 and having an IC50 below 1 uM).
\end_layout

\begin_layout Subsection
Results
\end_layout

\begin_layout Subsubsection
Separability-optimised Gene Sets
\end_layout

\begin_layout Standard
Using the default parameters of the SPEED query tools (constant cutoff if
 z<1%, expression>50%, overlap>20% and allowing non-unique genes), I obtained
 scores that were highly correlated between the different pathways.
 The Pearson correlations for each of the pathways across all cell lines
 is shown in figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "cor-before"

\end_inset

.
 For the optimised lists, I observed a much lower overall correlation of
 the pathway scores (figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "cor-after"

\end_inset

).
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/4.1_correlation_original.jpg
	lyxscale 50
	width 50col%

\end_inset


\begin_inset CommandInset label
LatexCommand label
name "cor-before"

\end_inset


\end_layout

\end_inset


\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\begin_inset Graphics
	filename figures/4.1_correlation_optimized.jpg
	lyxscale 50
	width 50col%

\end_inset


\begin_inset CommandInset label
LatexCommand label
name "cor-after"

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Correlation plots for GSEA scores per pathway across cell lines for the
 original SPEED lists (panel a) and our separation-optimized version (panel
 b).
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard
The values for the different gene list cutoff parameters that I selected
 after optimisation are listed in table 
\begin_inset CommandInset ref
LatexCommand ref
reference "tab:Parameter-selection-overview"

\end_inset

, including the number of genes in the signature and prAUC (training and
 test set) compared between the original cutoffs used in the query tool
 and my selection.
 Pathways where the optimisation of paramters yielded a better separation
 of control- vs.
 perturbed arrays are shown in bold (all of them).
\end_layout

\begin_layout Standard
\begin_inset Float table
wide false
sideways false
status open

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Parameter selection overview for each pathway.
 Z: Z-value cutoff (0.25-20), O: array overlap (20-80); E: overall expression
 cutoff (5-100), U: unique (+) or all (-) genes considered.
 Gene lists had to be between 50 and 250 genes to be considered, values
 for optimized and original lists are shown.
 Precision-recall AUC shown for training, cross-training for optimized lists
 and whole data set for optimized lists vs.
 the one obtained by using the original lists.
\begin_inset CommandInset label
LatexCommand label
name "tab:Parameter-selection-overview"

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Plain Layout
\align center
\begin_inset ERT
status open

\begin_layout Plain Layout


\backslash
centerline{
\end_layout

\end_inset


\lang british

\begin_inset Tabular
<lyxtabular version="3" rows="13" columns="11">
<features rotate="0" tabularvalignment="middle">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<column alignment="center" valignment="top">
<row>
<cell multirow="3" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
pathway
\end_layout

\end_inset
</cell>
<cell multicolumn="1" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
cutoffs used
\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" topline="true" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" topline="true" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" topline="true" bottomline="true" rightline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell multicolumn="1" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
# genes in list
\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell multicolumn="1" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
precision-recall AUC
\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell multicolumn="1" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
all arrays
\end_layout

\end_inset
</cell>
<cell multicolumn="2" alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
</row>
<row>
<cell multirow="4" alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
Z
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
O
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
E
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
U
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
opt
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
original
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
train
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
cv
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
opt
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" bottomline="true" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
original
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
H2O2
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
50
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
191
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
60
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.99
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
1.00
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.99
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.66
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
IL-1
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
60
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
75
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
141
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.91
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.99
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.93
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.85
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
JAK-STAT
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
70
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
162
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
114
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.78
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.87
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.81
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.68
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
MAPK_only
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
70
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
10
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
-
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
65
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
559
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.94
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.97
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.95
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.46
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
MAPK_PI3K
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
15
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
5
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
-
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
171
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
118
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.82
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.89
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.84
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.63
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
TLR
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
6.5
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
40
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
50
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
78
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
181
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.88
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.91
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.89
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.81
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
PI3K_only
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
15
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
30
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
227
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
67
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.80
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.97
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.83
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.49
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
TGFB
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
60
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
119
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
142
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.78
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.88
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.80
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.68
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
TNFa
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
1.5
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
50
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
70
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
-
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
56
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
259
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.77
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.99
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.81
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.66
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
VEGF
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
12
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
20
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
30
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
121
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
56
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.92
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.94
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.92
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.84
\end_layout

\end_inset
</cell>
</row>
<row>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
Wnt
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
7.5
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
30
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
5
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
+
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
195
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
83
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.93
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.94
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\series bold
\lang british
0.93
\end_layout

\end_inset
</cell>
<cell alignment="center" valignment="top" usebox="none">
\begin_inset Text

\begin_layout Plain Layout

\lang british
0.65
\end_layout

\end_inset
</cell>
</row>
</lyxtabular>

\end_inset


\lang english

\begin_inset ERT
status open

\begin_layout Plain Layout

}
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsubsection
Overlap of Gene Lists
\end_layout

\begin_layout Itemize
old with new cutoffs
\end_layout

\begin_layout Itemize
new with other gene lists (GO, pathway)
\end_layout

\begin_layout Subsubsection
Obtaining Pathway Scores from Gene Sets
\end_layout

\begin_layout Standard
\begin_inset Float table
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/4.1_heatmap.pdf
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Normalized GSEA scores for 1018 cell lines in the GDSC panel.
 Each row is a cell line (as indicated by its COSMIC ID), with the columns
 representing different pathways.
\begin_inset Note Note
status open

\begin_layout Plain Layout
would be good to order by pathways to compare to later model
\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsubsection
Associations between Pathway Scores and Tissues
\end_layout

\begin_layout Standard

\lang british
An overview of up- and down-regulated pathways (in terms of the inferred
 pathway scores by the SPEED platform with my modifications) is shown in
 figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "fig:tissue-heatmap"

\end_inset

.
 Relating this to known biology, the scores seem well supported by previously
 known evidence.
 A couple of examples to illustrate this are listed below.
\end_layout

\begin_layout Standard

\lang british
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/4.1_speed_tissue.pdf
	width 80col%

\end_inset


\end_layout

\begin_layout Plain Layout

\lang british
\begin_inset Caption Standard

\begin_layout Plain Layout

\lang british
Heatmap of inferred pathway activation scores for different tissues
\begin_inset CommandInset label
LatexCommand label
name "fig:tissue-heatmap"

\end_inset


\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Itemize

\lang british
JAK-STAT signalling is well-known to be upregulated in blood cancer cells
 
\begin_inset CommandInset citation
LatexCommand cite
key "Dutta2013-fg,Vainchenker2012-sv"

\end_inset

, including in particular AML 
\begin_inset CommandInset citation
LatexCommand cite
key "Lee2012-ts,Danial2000-xd"

\end_inset

, CML 
\begin_inset CommandInset citation
LatexCommand cite
key "Danial2000-xd"

\end_inset

, ALL 
\begin_inset CommandInset citation
LatexCommand cite
key "Vainchenker2012-sv"

\end_inset

, and DLBC 
\begin_inset CommandInset citation
LatexCommand cite
key "Gupta2012-zp"

\end_inset

.
 This correlates well with the inferred activity scores for JAK-STAT signalling.
 Similarly, TLR signalling has been shown to be induced by CpG oxydinucleotides
 in B- (DLBC, MM) and dentritic myeloid, but not T-cells 
\begin_inset CommandInset citation
LatexCommand cite
key "Rothenfusser2002-gi"

\end_inset

.
\end_layout

\begin_layout Itemize

\lang british
High production of reactive oxygen species has been shown to occur in certain
 mesotheliomas 
\begin_inset CommandInset citation
LatexCommand cite
key "Kahlos1999-py"

\end_inset

, and gliomas 
\begin_inset CommandInset citation
LatexCommand cite
key "Drukala2010-kj"

\end_inset

.
\end_layout

\begin_layout Itemize

\lang british
TGFB 
\begin_inset CommandInset citation
LatexCommand cite
key "Yamada1995-yi,Kjellman2000-om"

\end_inset

 and VEGF 
\begin_inset CommandInset citation
LatexCommand cite
key "Reardon2008-ot"

\end_inset

 expression have been shown to be increased gliomas, correlating with malignancy
 
\begin_inset CommandInset citation
LatexCommand cite
key "Kjellman2000-om,Leon1996-zu"

\end_inset

.
 Both were also increased in mesothelioma 
\begin_inset CommandInset citation
LatexCommand cite
key "Kuwahara2001-ru,Aoe2006-vc"

\end_inset

, and VEGF in melanoma 
\begin_inset CommandInset citation
LatexCommand cite
key "Rajabi2012-fj,Gajanin2010-ff"

\end_inset

 as well.
\end_layout

\begin_layout Itemize

\lang british
MAPK_only/MAPK_PI3K signalling seems to evenly distributed among non-blood
 cancer tissues.
 We found the highest activity of MAPK and MAPK_PI3K can be found in KIRC
 and BLCA/PAAD, respectively.
 However, the difference was a lot less apparent than for other pathways.
\end_layout

\begin_layout Subsubsection

\lang british
Pan-Cancer Drug Associations
\end_layout

\begin_layout Standard

\lang british
Linear associations of inferred pathway activity within all tissues and
 drug response are shown in figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "fig:pancan-volcano"

\end_inset

.
 Negative regression slopes (left side of the graph, green) indicate sensitivity
 markers, i.e.
 a higher pathway activation score correlates with a lower IC50.
 Positive regression slopes (right side, red) indicate resistance markers,
 i.e.
 higher activation scores correlate with higher IC50s.
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/4.1_volcano_pancan.pdf
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout
Volcano plot of linear associations of inferred pathway activity within
 all tissues and drug response.
 Tissue of origin used as a covarate in the regression.
 P-values FDR-adjusted.
 Negative regression slopes (left side of the graph, green) indicate sensitivity
 markers, i.e.
 a higher pathway activation score correlates with a lower IC50.
 Positive regression slopes (right side, red) indicate resistance markers,
 i.e.
 higher activation scores correlate with higher IC50s.
\begin_inset CommandInset label
LatexCommand label
name "fig:pancan-volcano"

\end_inset


\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Standard

\lang british
Sensitivity markers:
\end_layout

\begin_layout Itemize

\lang british
RDEA119 
\begin_inset CommandInset citation
LatexCommand cite
key "Iverson2009-uu"

\end_inset

, PD-0325901 
\begin_inset CommandInset citation
LatexCommand cite
key "Ciuffreda2009-iz"

\end_inset

, and CI-1040 
\begin_inset CommandInset citation
LatexCommand cite
key "Allen2003-pz"

\end_inset

 are all MEK inhibitors and are thus to be expected to be more effective
 in cell lines where MAPK signalling is more active.
 In fact, the strongest associations are between those drugs and MAPK_PI3K
 signalling.
 However, MAPK and PI3K are difficult to distinguish in expression response
 due to pathway crosstalk 
\begin_inset CommandInset citation
LatexCommand cite
key "Parikh2010-uj"

\end_inset

.
\end_layout

\begin_layout Itemize

\lang british
BIBW2992 and Gefitinib showed higher efficacy with PI3K_only activity.
 As both are are EGFR inhibitors and PI3K is known to cause resistance to
 those 
\begin_inset CommandInset citation
LatexCommand cite
key "Jeannot2014-av"

\end_inset

, this result is surprising because the association is stronger than with
 MAPK_only or MAPK_PI3K.
\end_layout

\begin_layout Itemize

\lang british
We found sensitivity correlating with Wnt activity for the drugs Etoposide,
 QS11, and GSK-650394.
 QS11 modulates ARF activity and B-catenin localisation 
\begin_inset CommandInset citation
LatexCommand cite
key "Zhang2007-fu"

\end_inset

, which may offer a treatment strategy for Wnt-driven tumours.
 GSK-650394 targets SGK1, which is activated by Wnt/B-catenin signalling
 and has been shown to inhibit ROS-induced apoptosis in liver cells 
\begin_inset CommandInset citation
LatexCommand cite
key "Tao2013-sj"

\end_inset

.
 Etoposide induces DNA damage and senescence, where this process may be
 inhibited by negative feedback by SFRP1 
\begin_inset CommandInset citation
LatexCommand cite
key "Elzi2012-mv"

\end_inset

 due to Wnt signalling.
\end_layout

\begin_layout Itemize

\lang british
FTI-277 is more effective when reactive oxygen response (H2O2) is active.
 Farnesyl transferase inhibitors are known to induce DNA damage via ROS
 
\begin_inset CommandInset citation
LatexCommand cite
key "Pan2005-on"

\end_inset

, which may cause growth arrest or apoptosis in cells that already suffer
 ROS damage.
\end_layout

\begin_layout Itemize

\lang british
AZD6482 is a PI3K inhibitor 
\begin_inset CommandInset citation
LatexCommand cite
key "Nylander2012-cl"

\end_inset

, for which cells show increased sensitivity in our study when TNFa signalling
 is active.
 While the latter can be both oncogenic and tumour-suppressive 
\begin_inset CommandInset citation
LatexCommand cite
key "Pikarsky2006-ba"

\end_inset

, it has been shown that PI3K activation is necessary for NFKb-mediated
 cell survival in DLBC 
\begin_inset CommandInset citation
LatexCommand cite
key "Kloo2011-ut"

\end_inset

 and the combination of PI3K inhibition and active TNFa causes apoptosis
 in vitiligous keratinocytes 
\begin_inset CommandInset citation
LatexCommand cite
key "Kim2007-db"

\end_inset

.
\end_layout

\begin_layout Itemize

\lang british
TNFalpha 
\begin_inset CommandInset citation
LatexCommand cite
key "Sleijfer1998-vs"

\end_inset

 signalling has been shown to be increased after Bleomycin treatment, thereby
 mediating cytotoxicity.
 It can be hypothesised that if this pathway is active in cell lines, they
 are more likely to be affected by this.
\end_layout

\begin_layout Standard

\lang british
Resistance markers:
\end_layout

\begin_layout Itemize

\lang british
EHT 1864 is a Rac-family GTPase inhibitor 
\begin_inset CommandInset citation
LatexCommand cite
key "Shutes2007-mi"

\end_inset

, and MAPK_PI3K signalling is associated with resistance to this drug.
 Rac1 is known to be involved in MAPK signalling specifically for cancer
 development 
\begin_inset CommandInset citation
LatexCommand cite
key "Khosravi-Far1995-mk"

\end_inset

, so cells with a higher MAPK activity may be less susceptible to Rac1 inhibitio
n.
\end_layout

\begin_layout Standard

\lang british
To give an example of the relationship between inferred pathway activity
 and drug response for different tissues, a linear fit of MAPK_PI3K activity
 is shown in relation to the log IC50 of RDEA119 in figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "fig:RDEA-MAPK"

\end_inset

.
 For low grad glioma (LGG), neuroblastoma (NB), and cervical carcinoma,
 the inferred activity explains about a third of the total variance in drug
 response.
 This is slightly lower for the rest of tissues, with 8 tissues showing
 a significant association between the drug and the pathway.
\begin_inset Note Note
status open

\begin_layout Plain Layout

\lang british
compare to a mutation here?
\end_layout

\end_inset


\end_layout

\begin_layout Subsubsection
Tissue-specific Drug Associations
\end_layout

\begin_layout Standard

\lang british
In addition to calculating the strongest associations within all tissues,
 we also calculated the ones for each tissue separately, associations for
 which are shown in figure 
\begin_inset CommandInset ref
LatexCommand ref
reference "fig:tissue-drug-assocs"

\end_inset

.
\end_layout

\begin_layout Standard
\begin_inset Float figure
wide false
sideways false
status open

\begin_layout Plain Layout
\align center
\begin_inset Graphics
	filename figures/4.1_volcano_tissue.pdf
	width 100col%

\end_inset


\end_layout

\begin_layout Plain Layout
\begin_inset Caption Standard

\begin_layout Plain Layout

\lang british
Associations between inferred pathway activity and drug response for individual
 tissues.
 FDR set at 20%.
\begin_inset CommandInset label
LatexCommand label
name "fig:tissue-drug-assocs"

\end_inset


\end_layout

\end_inset


\end_layout

\end_inset


\end_layout

\begin_layout Subsection
Discussion
\end_layout

\begin_layout Standard
Using pathway-responsive genes instead of pathway expression to infer signaling
 activity makes a lot of sense: we look at the footprint of the actual signaling
 activity (the expression changes downstream of a signaling pathway) and
 not the potential mediators (protein kinases, among others) by mRNA expression
 level that is a lot further removed from the actual signaling going on
 in a cell.
 However, the SPEED platform has some issues in terms of the level in which
 its pathways are correlated to one another: If we did calculate drug associatio
ns with the original scores, hits would be groups where a given drug is
 correlated with all pathways in about the same extent.
 This is likely due to how they only evaluated gene lists by their overlap
 with Gene Ontology categories, and not how well its enrichment scores are
 able to differentiate between microarrays where a given pathway perturbation
 is present and those where it is absent.
 And it is not useful for our purposes.
\end_layout

\begin_layout Standard
We thus have a need for scores that are more potent in distinguishing the
 gene expression footprints from one pathway to another.
 A way to do this in the existing platform is to no longer require that
 the signature genes from all pathways are obtained using the same cutoffs
 of the author's 4 parameters, but instead optimise them in way so that
 they are best able to tell apart the pathways one from another.
 Looking at the correlations between the original cutoffs and the ones I
 suggest after the cross-validated optimisation, I know that this worked
 at least on those terms.
\end_layout

\begin_layout Standard
The next question to answer is whether we get more meaningful drug associations.
 Looking at the volcano plot for both pan-cancer and individual tissues,
 associations are, for one, not between a drug and all pathways, and for
 the other much better supported when searching for literature corresponding
 to the top hits.
\end_layout

\begin_layout Standard
However, there is still a wealth of potential issues with the current model,
 many of which can be traced back to using the original platform: (1) The
 authors use raw microarray data as well as processed data.
 For the processed data, we have no idea of what the original authors did
 with their data to arrive at the expression levels they report.
 Sometimes they report this in their respective experimental or data analysis
 procedures, but often they don't.
 There is a potential of all sorts of biases that we can not control for.
 (2) The platform as it currently stands needs four paramters to be speficied,
 each of which corresponds to a somewhat arbitrary cutoff.
 Even if we ignore this, they limit that method in a way that does not support
 down-regulated genes at all (as the z-scores are filtered by top percentile
 only).
 (3) We bias the selection of genes to the ones most commonly found in microarra
ys.
 If a gene is highly upregulated but not present in arrays and thus failing
 the overlap cutoff, we would lose it.
\end_layout

\begin_layout Standard
I am thus inclined to argue that, while the optimisation of paramters yielded
 vast improvements in terms of correlatedness of scores and resulting drug
 associations, it still has enough drawbacks the warrant a different approach
 while keeping the overall idea of using pathway-responsive genes as signature
 for pathway activity.
\end_layout

\begin_layout Standard
\begin_inset CommandInset bibtex
LatexCommand bibtex
bibfiles "references"
options "plain"

\end_inset


\end_layout

\end_body
\end_document
